GIMAP6

GIMAP6 is a lymphocyte-enriched GTPase that safeguards peripheral T cell survival and vascular integrity by coordinating autophagy, redox balance, and anti-apoptotic signaling. It forms a ternary complex with GABARAPL2 and GIMAP7, is recruited to autophagosomes upon starvation, and is required for normal autophagic flux; conditional deletion in mice causes accumulation of lipidated LC3-II and phospho-SQSTM1, elevated mitochondrial mass, and a 50–70% reduction in peripheral T cells (PMID:24204963, PMID:29718959, PMID:35551368). Recombinant GIMAP6 possesses both GTPase and ATPase activity and protects T cells from apoptosis through a mechanism involving NF-κB/p65 phosphorylation, independent of its hydrolytic activity (PMID:28381553). Biallelic loss-of-function mutations in human GIMAP6 cause a primary immune deficiency characterized by lymphopenia and recurrent infections, and GIMAP6 deficiency drives inflammatory vasculopathy and accelerated atherosclerosis in mice (PMID:33328581, PMID:35551368).

1. 2013 High

   Identifying a direct GIMAP6–GABARAPL2 interaction and starvation-induced autophagosomal recruitment established GIMAP6 as a participant in the autophagy machinery, answering how a lymphocyte GTPase connects to vesicular degradation.

   Evidence Biotin-tag affinity purification, chemical cross-linking, deletion mutagenesis, and fluorescence co-localization with autophagosomal markers in Jurkat T cells

   PMID:24204963

   Open questions at the time

   • The C-terminal interaction domain was mapped by deletion but no structural model of the GIMAP6–GABARAPL2 interface exists
   • Whether GIMAP6 promotes autophagosome biogenesis or acts at a later fusion/maturation step was unresolved
   • In vivo relevance of the interaction was not tested
2. 2017 High

   Demonstrating that GIMAP6 has dual GTPase/ATPase activity yet protects T cells from apoptosis independently of hydrolysis resolved the question of whether its enzymatic function underlies its pro-survival role, and linked it to NF-κB signaling.

   Evidence In vitro enzymatic assays on purified recombinant protein, siRNA knockdown with multiple apoptotic stimuli in Jurkat cells, overexpression rescue in Huh-7 cells, and phospho-p65 western blots

   PMID:28381553

   Open questions at the time

   • The mechanism by which GIMAP6 activates NF-κB/p65 independently of GTPase activity was not defined
   • Whether autophagy and anti-apoptotic functions are mechanistically linked or independent pathways was unclear
3. 2018 High

   Conditional Gimap6 deletion in mouse lymphocytes proved the gene is essential for peripheral T cell homeostasis and normal autophagic flux in vivo, translating earlier cell-line observations into a physiological context.

   Evidence CD2-Cre and tamoxifen-inducible conditional knockout mice with flow cytometry, western blot for LC3-II/phospho-SQSTM1/phospho-TBK1, and electron microscopy

   PMID:29718959

   Open questions at the time

   • Relative contributions of autophagy block versus apoptosis sensitivity to T cell loss were not disentangled
   • Non-lymphocyte roles of GIMAP6 were not explored
4. 2020 Medium

   Identification of biallelic GIMAP6 loss-of-function in human patients with lymphopenia and recurrent infections established GIMAP6 deficiency as a cause of primary immune deficiency, validating mouse findings in humans.

   Evidence Whole-exome sequencing, protein absence by western blot, apoptosis and lymphocyte function assays in patient cells

   PMID:33328581

   Open questions at the time

   • Single-family study; replication in independent kindreds was needed
   • Downstream molecular pathway disrupted in patient lymphocytes was not characterized
5. 2022 High

   Discovery of the GIMAP6–GABARAPL2–GIMAP7 ternary complex and IFN-γ-driven induction, together with defects in autophagy, redox regulation, and PUFA-lipid homeostasis in GIMAP6-deficient cells and mice, unified the autophagy, metabolic, and immune functions into a single framework and revealed a non-lymphocyte role in kidney endothelium.

   Evidence Human patient genetics and Gimap6−/− mice with co-immunoprecipitation, metabolomics, autophagy assays, IFN-γ stimulation, and renal histopathology

   PMID:35551368

   Open questions at the time

   • How the ternary complex regulates GTPase activity at a structural level is unknown
   • Whether the lipid-homeostasis defect is a direct consequence of impaired autophagy or an independent function of GIMAP6 is unresolved
   • The mechanism linking GIMAP6 to endothelial cell pathology was not defined
6. 2023 Medium

   Placement of GIMAP6 downstream of two independent ceRNA axes (GAS6-AS1/miR-24-3p and EPB41L4A-AS1/miR-105-5p) in lung adenocarcinoma cells defined post-transcriptional regulation of GIMAP6 and suggested a growth-suppressive role outside the immune compartment.

   Evidence Dual-luciferase reporters, RNA pull-down, functional rescue, and proliferation assays in NSCLC cell lines

   PMID:34513660 PMID:36734855

   Open questions at the time

   • ceRNA sponge mechanisms have limited in vivo validation
   • Whether GIMAP6's tumor-suppressive effect operates through autophagy or a distinct pathway is unknown

• Key unresolved questions include the structural basis of the GIMAP6–GABARAPL2–GIMAP7 complex, whether the autophagy and anti-apoptotic functions are mechanistically separable, the direct molecular link between GIMAP6 and lipid/redox homeostasis, and the cell-type-specific contributions (lymphocytes vs. endothelium) to cardiovascular disease.
• No atomic-resolution structure of GIMAP6 or its complexes
• Relative contribution of autophagy versus anti-apoptotic signaling to lymphocyte and vascular phenotypes is unresolved
• Endothelial-specific conditional knockout has not been reported